Earnings ·
Starling Oncology reports Q3 revenue of $169.8M, turns Adjusted EBITDA positive at $3.4M
DFPHStarling Oncology, Inc.
Starling Oncology reported third-quarter 2026 consolidated revenue of $169.8 million, a 24.3% increase from the prior year period. The company posted an adjusted EBITDA of positive $3.4 million, marking its second consecutive quarter of profitability on this metric and beating management's outlook range of $0.5 million to $1.5 million. Net loss narrowed to $15.7 million compared to $16.5 million in the prior year, while gross profit rose 62.1% to $30.7 million. Specialty pharmacy revenue surged 44% year over year to $109 million with a 24 percent gross margin, and capitated revenue grew 40%. The company affirmed its full-year 2026 guidance for adjusted EBITDA of $4 million to $6 million and raised the lower end of its revenue outlook to $650 million. Starling Oncology operates as a value-based community oncology group delivering specialized cancer care across multiple states.